drugset / Trial / NCT00547144
Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine the safety, feasibility and appropriate dendritic cell dose to vaccinate patients with pancreas cancer
Timeline
- Start
- 2005-10
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |